yulkapopkova / iStockphoto.com
Pharmaceutical company UCB injects a significant amount of revenue into R&D, but it is mindful of the risks attached to drug investment. Global head of IP Stéphane Drouin explains more in an interview with LSIPR.
“In the United States of America, healthcare is not a privilege for the fortunate few—it is a right,” Barack Obama said in 2013 when he spoke as President about the Patient Protection and Affordable Care Act, which had been signed into law in 2010.
The act, also known as ‘Obamacare’, aims to give more Americans access to affordable health insurance.
President Donald Trump is now trying to repeal Obamacare with the help of Republican lawmakers.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
LSIPR 50 2017, Stéphane Drouin, External collaboration, R&D, neurology, immunology, UCB, Vimpat, innovative technology
